La Jolla Pharmaceutical Company Added to NASDAQ Biotechnology Index

La Jolla Pharmaceutical Company Added to NASDAQ Biotechnology Index 


SAN DIEGO, Nov. 14  /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company 
today announced that it has been selected to be added to the NASDAQ
Biotechnology Index  effective November 24, 2003. The NASDAQ Biotechnology Index
includes companies primarily engaged in using biomedical research for the
discovery or development of novel treatments or cures for human disease.  All
securities in the Index are listed on the NASDAQ National Market and meet
minimum requirements, including market value, average daily share volume, and
seasoning as a public company.  The Index is ranked on a semi-annual basis in
May and November and serves as the basis for the iShares Nasdaq Biotechnology
Index Fund(SM) .  For more information about the NASDAQ Biotechnology Index,
including eligibility criteria, visit http://www.nasdaq.com/ .

La Jolla Pharmaceutical Company is a biotechnology company developing
therapeutics for antibody-mediated autoimmune diseases afflicting several
million people in the United States and Europe.  The Company is developing
Riquent(TM), formerly known as LJP 394, for the treatment of lupus kidney
disease, a leading cause of sickness and death in patients with lupus.  The
Company is also developing LJP 1082 for the treatment of antibody-mediated
thrombosis, a condition in which patients suffer from recurrent stroke, deep-
vein thrombosis and other thrombotic events.  The Company's common stock is
traded on The Nasdaq Stock Market under the symbol LJPC.  For more information
about the Company, visit its Web site: http://www.ljpc.com/ .

This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995.  Forward-looking statements
involve significant risks and uncertainties, and a number of factors, both
foreseen and unforeseen, could cause actual results to differ materially from
our current expectations.  Readers are cautioned to not place undue reliance
upon forward-looking statements, which speak only as of the date hereof, and we
undertake no obligation to update forward-looking statements to reflect events
or circumstances occurring after the date hereof. Interested parties are urged
to review the risks described in our Annual Report on Form 10-K for the year
ended December 31, 2002, and in other reports and registration statements that
we file with the Securities and Exchange Commission from time to time. 

DATASOURCE: La Jolla Pharmaceutical Company



CONTACT:  Andrew Wiseman, Ph.D., Sr. Director of Business Development and

Investor Relations of La Jolla Pharmaceutical Company, [phone],

; or media, Virginia Amann, [phone],

, or Trista Morrison, [phone], , both

of Atkins + Associates, for La Jolla Pharmaceutical Company



Web site:  http://www.nasdaq.com/ 

Web site:  http://www.ljpc.com/ 

Copyright